| | | |
| | | |
1. | Tozinameran (Pfizer‑BioNTech COVID‑19 vaccine or Comirnaty COVID‑19 vaccine) |
|
| (1) | One dose of the approved vaccine opposite, administered to a Type T recovered individual at least 28 days after the recovered individual first tested positive for SARS‑CoV‑2. |
|
| 14th day after the dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (2) | One dose of the approved vaccine opposite, administered to a Type S recovered individual after his or her recovery from the COVID‑19 infection. |
|
| 14th day after the dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (3) | Two doses of the approved vaccine opposite, administered at least 17 days apart. |
|
| 14th day after the second dose is administered in accordance with the second column. |
| 270th day (including that day) after the day the second dose is administered. |
|
| (4) | One dose of the approved vaccine opposite, followed by a dose of another approved vaccine that is not a defined approved vaccine, administered at least 17 days after the firstmentioned dose is administered. |
|
| 14th day after the second dose is administered in accordance with the second column. |
| 270th day (including that day) after the second dose is administered. |
|
| (5) | One dose of the approved vaccine opposite, followed by a dose of a defined approved vaccine, administered at least 17 days after the firstmentioned dose is administered. |
|
| 14th day after the second dose is administered in accordance with the second column. |
| 120th day (including that day) after the day the second dose is administered. |
|
| (6) | Two doses of the approved vaccine opposite or one dose thereof in combination with a dose of another approved vaccine where the doses are administered at such other intervals as may be allowed by the Director. |
|
| 14th day after the second dose is administered in accordance with the second column. |
| The following day (including that day) after the day the second dose is administered: |
(a) | 120th day where the second dose is a defined approved vaccine; |
|
(b) | 270th day for any other approved vaccine. |
|
|
| (7) | Three doses of the approved vaccine opposite, where the first 2 doses are administered at least 17 days apart, and where the second and third doses are administered at least 86 days apart. |
|
| The day the third dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (8) | Two doses of the approved vaccine opposite, followed by one dose of another approved vaccine, where the first 2 doses are administered at least 17 days apart, and where the second and third doses are administered at least 86 days apart. |
|
| The day the third dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (9) | One dose of the approved vaccine opposite, followed by 2 doses of another approved vaccine that is not a defined approved vaccine or a combination of approved vaccines none of which is a defined approved vaccine, where the first 2 doses are administered at least 17 days apart, and where the second and third doses are administered at least 86 days apart. |
|
| The day the third dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (10) | One dose of the approved vaccine opposite, followed by 2 doses of any defined approved vaccine or combination of defined approved vaccines, where the respective doses are each administered at least 17 days apart. |
|
| The day the third dose is administered in accordance with the second column. |
| 270th day (including that day) after the day the third dose is administered. |
|
| (11) | Vaccination in accordance with paragraph (6) where the second dose is a defined approved vaccine, followed by another dose of any defined approved vaccine, where the second and third doses are administered at least 17 days apart. |
|
| The day the third dose is administered in accordance with the second column. |
| 270th day (including that day) after the day the third dose is administered. |
|
| (12) | Vaccination in accordance with paragraph (6) where the second dose is an approved vaccine that is not a defined approved vaccine, followed by a third dose of any approved vaccine that is not a defined approved vaccine, where the second and third doses are administered at least 86 days apart. |
|
| The day the third dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (13) | At least 3 doses one of which is the approved vaccine opposite, and where the second and third doses are administered at a shorter interval than as specified in paragraph (7), (8), (9) or (12) and allowed by the Director. |
|
| The day the third dose is administered in accordance with the second column. |
| 270th day (including that day) after the day the second dose is administered plus a period fixed by the Director, being not more than 85 days and corresponding to the actual interval between the second and third doses. |
|
| (14) | Vaccination in accordance with paragraph (10) followed by a fourth dose of any approved vaccine administered at least 86 days after the third dose is administered. |
|
| The day the fourth dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (15) | At least 4 doses where vaccination is in accordance with paragraph (10) for the first 3 doses and the fourth dose is any approved vaccine, and where the third and fourth doses are administered at a shorter interval than as specified in paragraph (14) and allowed by the Director. |
|
| The day the fourth dose is administered in accordance with the second column. |
| 270th day (including that day) after the day the third dose is administered plus a period fixed by the Director, being not more than 85 days and corresponding to the actual interval between the third and fourth doses. |
|
2. | Spikevax (Moderna COVID‑19 vaccine) |
|
| (1) | One dose of the approved vaccine opposite, administered to a Type T recovered individual at least 28 days after the recovered individual first tested positive for SARS‑CoV‑2. |
|
| 14th day after the dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (2) | One dose of the approved vaccine opposite, administered to a Type S recovered individual after his or her recovery from the COVID‑19 infection. |
|
| 14th day after the dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (3) | Two doses of the approved vaccine opposite, administered at least 24 days apart. |
|
| 14th day after the second dose is administered in accordance with the second column. |
| 270th day (including that day) after the day the second dose is administered. |
|
| (4) | One dose of the approved vaccine opposite, followed by a dose of another approved vaccine that is not a defined approved vaccine, administered at least 17 days after the firstmentioned dose is administered. |
|
| 14th day after the second dose is administered in accordance with the second column. |
| 270th day (including that day) after the day the second dose is administered. |
|
| (5) | One dose of the approved vaccine opposite, followed by a dose of a defined approved vaccine, administered at least 17 days after the firstmentioned dose is administered. |
|
| 14th day after the second dose is administered in accordance with the second column. |
| 120th day (including that day) after the day the second dose is administered. |
|
| (6) | Two doses of the approved vaccine opposite or one dose thereof in combination with a dose of another approved vaccine, where the doses are administered at such other intervals as may be allowed by the Director. |
|
| 14th day after the second dose is administered in accordance with the second column. |
| The following day (including that day) after the day the second dose is administered: |
(a) | 120th day where the second dose is a defined approved vaccine; |
|
(b) | 270th day for any other approved vaccine. |
|
|
| (7) | Three doses of the approved vaccine opposite, where the first 2 doses are administered at least 24 days apart, and where the second and third doses are administered at least 86 days apart. |
|
| The day the third dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (8) | Two doses of the approved vaccine opposite followed by one dose of any other approved vaccine, where the first 2 doses are administered at least 24 days apart, and where the second and third doses are administered at least 86 days apart. |
|
| The day the third dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (9) | One dose of the approved vaccine opposite, followed by 2 doses of another approved vaccine that is not a defined approved vaccine or a combination of approved vaccines none of which is a defined approved vaccine, where the first 2 doses are administered at least 17 days apart, and where the second and third doses are administered at least 86 days apart. |
|
| The day the third dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (10) | One dose of the approved vaccine opposite, followed by 2 doses of any defined approved vaccine or combination of defined approved vaccines, where the respective doses are each administered at least 17 days apart. |
|
| The day the third dose is administered in accordance with the second column. |
| 270th day (including that day) after the day the third dose is administered. |
|
| (11) | Vaccination in accordance with paragraph (6) where the second dose is a defined approved vaccine, followed by another dose of any defined approved vaccine, where the second and third doses are administered at least 17 days apart. |
|
| The day the third dose is administered in accordance with the second column. |
| 270th day (including that day) after the day the third dose is administered. |
|
| (12) | Vaccination in accordance with paragraph (6) where the second dose is an approved vaccine that is not a defined approved vaccine, followed by a third dose of any approved vaccine that is not a defined approved vaccine, where the second and third doses are administered at least 86 days apart. |
|
| The day the third dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (13) | At least 3 doses of approved vaccines, one of which is the approved vaccine opposite, and where the second and third doses are administered at a shorter interval than as specified in paragraph (7), (8), (9) or (12) and allowed by the Director. |
|
| The day the third dose is administered in accordance with the second column. |
| 270th day (including that day) after the day the second dose is administered plus a period fixed by the Director, being not more than 85 days and corresponding to the actual interval between the second and third doses. |
|
| (14) | Vaccination in accordance with paragraph (10) followed by a fourth dose of any approved vaccine administered at least 86 days after the third dose is administered. |
|
| The day the fourth dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (15) | At least 4 doses where vaccination is in accordance with paragraph (10) for the first 3 doses and the fourth dose is any approved vaccine, and where the third and fourth doses are administered at a shorter interval than as specified in paragraph (14) and allowed by the Director. |
|
| The day the fourth dose is administered in accordance with the second column. |
| 270th day (including that day) after the day the third dose is administered plus a period fixed by the Director, being not more than 85 days and corresponding to the actual interval between the third and fourth doses. |
|
3. | Covishield COVID‑19 vaccine or Vaxzevria (AstraZeneca COVID‑19 vaccine) |
|
| (1) | One dose of the approved vaccine opposite, administered to a Type T recovered individual at least 28 days after the recovered individual first tested positive for SARS‑CoV‑2. |
|
| 14th day after the dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (2) | One dose of the approved vaccine opposite, administered to a Type S recovered individual after his or her recovery from the COVID‑19 infection. |
|
| 14th day after the dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (3) | Two doses of the approved vaccine opposite, administered at least 24 days apart. |
|
| 14th day after the second dose is administered in accordance with the second column. |
| 270th day (including that day) after the day the second dose is administered. |
|
| (4) | One dose of the approved vaccine opposite, followed by a dose of another approved vaccine that is not a defined approved vaccine, administered at least 17 days after the firstmentioned dose is administered. |
|
| 14th day after the second dose is administered in accordance with the second column. |
| 270th day (including that day) after the day the second dose is administered. |
|
| (5) | One dose of the approved vaccine opposite, followed by a dose of a defined approved vaccine, administered at least 17 days after the firstmentioned dose is administered. |
|
| 14th day after the second dose is administered in accordance with the second column. |
| 120th day (including that day) after the day the second dose is administered. |
|
| (6) | Two doses of the approved vaccine opposite or one dose thereof in combination with a dose of another approved vaccine, where the doses are administered at such other intervals as may be allowed by the Director. |
|
| 14th day after the second dose is administered in accordance with the second column. |
| The following day (including that day) after the day the second dose is administered: |
(a) | 120th day where the second dose is a defined approved vaccine; |
|
(b) | 270th day for any other approved vaccine. |
|
|
| (7) | Three doses of the approved vaccine opposite, where the first 2 doses are administered at least 24 days apart, and where the second and third doses are administered at least 86 days apart. |
|
| The day the third dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (8) | Two doses of the approved vaccine opposite administered at least 24 days apart, followed by one dose of another approved vaccine administered at least 86 days after the second dose is administered. |
|
| The day the third dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (9) | One dose of the approved vaccine opposite, followed by 2 doses of another approved vaccine that is not a defined approved vaccine or a combination of approved vaccines none of which is a defined approved vaccine, where the first 2 doses are administered at least 17 days apart, and where the second and third doses are administered at least 86 days apart. |
|
| The day the third dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (10) | One dose of the approved vaccine opposite, followed by 2 doses of any defined approved vaccine or combination of defined approved vaccines, where the respective doses are each administered at least 17 days apart. |
|
| The day the third dose is administered in accordance with the second column. |
| 270th day (including that day) after the day the third dose is administered. |
|
| (11) | Vaccination in accordance with paragraph (6) where the second dose is a defined approved vaccine, followed by another dose of any defined approved vaccine, where the second and third doses are administered at least 17 days apart. |
|
| The day the third dose is administered in accordance with the second column. |
| 270th day (including that day) after the day the third dose is administered. |
|
| (12) | Vaccination in accordance with paragraph (6) where the second dose is an approved vaccine that is not a defined approved vaccine, followed by a third dose of any approved vaccine that is not a defined approved vaccine, where the second and third doses are administered at least 86 days apart. |
|
| The day the third dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (13) | At least 3 doses of approved vaccines, one of which is the approved vaccine opposite, and where the second and third doses are administered at a shorter interval than as specified in paragraph (7), (8), (9) or (12) and allowed by the Director. |
|
| The day the third dose is administered in accordance with the second column. |
| 270th day (including that day) after the day the second dose is administered plus a period fixed by the Director, being not more than 85 days and corresponding to the actual interval between the second and third doses. |
|
| (14) | Vaccination in accordance with paragraph (10) followed by a fourth dose of any approved vaccine administered at least 86 days after the third dose is administered. |
|
| The day the fourth dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (15) | At least 4 doses where vaccination is in accordance with paragraph (10) for the first 3 doses and the fourth dose is any approved vaccine, and where the third and fourth doses are administered at a shorter interval than as specified in paragraph (14) and allowed by the Director. |
|
| The day the fourth dose is administered in accordance with the second column. |
| 270th day (including that day) after the day the third dose is administered plus a period fixed by the Director, being not more than 85 days and corresponding to the actual interval between the third and fourth doses. |
|
4. | Johnson & Johnson’s (J&J) Janssen COVID‑19 vaccine |
|
| (1) | One dose of the approved vaccine opposite, administered to a Type T recovered individual at least 28 days after the recovered individual first tested positive for SARS‑CoV‑2. |
|
| 14th day after the dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (2) | One dose of the approved vaccine opposite, administered to a Type S recovered individual after his or her recovery from the COVID‑19 infection. |
|
| 14th day after the dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (3) | One dose of the approved vaccine opposite. |
|
| 14th day after the dose is administered. |
| 270th day (including that day) after the day the dose is administered. |
|
| (4) | One dose of the approved vaccine opposite, followed by a dose of another approved vaccine, administered at least 86 days after the firstmentioned dose was administered. |
|
| The day the second dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (5) | At least 2 doses of approved vaccines, one of which is the approved vaccine opposite, and where the doses are administered at a shorter interval than as specified in paragraph (4) and allowed by the Director. |
|
| The day the second dose is administered in accordance with the second column. |
| 270th day (including that day) after the day the first dose is administered plus a period fixed by the Director, being not more than 85 days and corresponding to the actual interval between the first and second doses. |
|
5. | Sinopharm COVID‑19 vaccine |
|
| (1) | One dose of the approved vaccine opposite, administered to a Type T recovered individual at least 28 days after the recovered individual first tested positive for SARS‑CoV‑2. |
|
| 14th day after the dose is administered in accordance with the second column. |
| 120th day (including that day) after the day the dose is administered. |
|
| (2) | One dose of the approved vaccine opposite, administered to a Type S recovered individual after his or her recovery from the COVID‑19 infection. |
|
| 14th day after the dose is administered in accordance with the second column. |
| 120th day (including that day) after the day the dose is administered. |
|
| (3) | Two doses of the approved vaccine opposite, or a combination of defined approved vaccines, administered to a Type T recovered individual, the first dose of which is administered at least 28 days after the recovered individual first tested positive for SARS‑CoV‑2 and the second dose at least 17 days after the firstmentioned dose was administered. |
|
| 14th day after the second dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (4) | Two doses of the approved vaccine opposite, or a combination of defined approved vaccines, administered to a Type S recovered individual after his or her recovery from the COVID‑19 infection, where the respective doses are each administered at least 17 days apart. |
|
| 14th day after the second dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (5) | One dose of the approved vaccine opposite and a second dose of another approved vaccine that is not a defined approved vaccine, administered to a Type T recovered individual, the first dose of which is administered at least 28 days after the recovered individual first tested positive for SARS‑CoV‑2 and the second dose at least 17 days after the firstmentioned dose was administered. |
|
| 14th day after the second dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (6) | One dose of the approved vaccine opposite and a second dose of another approved vaccine that is not a defined approved vaccine, administered to a Type S recovered individual after his or her recovery from the COVID‑19 infection, where the respective doses are each administered at least 17 days apart. |
|
| 14th day after the second dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (7) | Two doses of the approved vaccine opposite, administered at least 17 days apart. |
|
| 14th day after the second dose is administered in accordance with the second column. |
| 120th day (including that day) after the day the second dose is administered. |
|
| (8) | One dose of the approved vaccine opposite, followed by a dose of another approved vaccine, administered at least 17 days after the firstmentioned dose is administered. |
|
| 14th day after the second dose is administered in accordance with the second column. |
| 120th day (including that day) after the day the second dose is administered. |
|
| (9) | Three doses of the defined approved vaccine opposite, where each dose is administered at least 17 days apart. |
|
| The day the third dose is administered in accordance with the second column. |
| 270th day (including that day) after the day the third dose is administered. |
|
| (10) | Two doses of the defined approved vaccine opposite followed by a third dose either of Sinovac‑Coronavac COVID‑19 vaccine or another approved vaccine that is not a defined approved vaccine, where each dose is administered at least 17 days apart. |
|
| The day the third dose is administered in accordance with the second column. |
| 270th day (including that day) after the day the third dose is administered. |
|
| (11) | One dose of the defined approved vaccine opposite, followed by a dose of another approved vaccine that is not a defined approved vaccine, followed by a third dose of a defined approved vaccine, where each dose is administered at least 17 days apart. |
|
| The day the third dose is administered in accordance with the second column. |
| 270th day (including that day) after the day the third dose is administered. |
|
| (12) | One dose of the defined approved vaccine opposite, followed by a dose of Sinovac‑Coronavac COVID‑19 vaccine, then followed by a third dose of any approved vaccine, where each dose is administered at least 17 days apart. |
|
| The day the third dose is administered in accordance with the second column. |
| 270th day (including that day) after the day the third dose is administered. |
|
| (13) | Vaccination as described in paragraph (9) followed by a fourth dose of any approved vaccine administered at least 86 days after the third dose is administered. |
|
| The day the fourth dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (14) | Vaccination as described in paragraph (10), (11) or (12) followed by a fourth dose of any approved vaccine administered at least 86 days after the third dose is administered. |
|
| The day the fourth dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (15) | At least 4 doses of approved vaccines, one of which is the approved vaccine opposite, and where the third and fourth doses are administered at a shorter interval than as specified in paragraph (13) or (14) and allowed by the Director. |
|
| The day the fourth dose is administered in accordance with the second column. |
| 270th day (including that day) after the start of the period in paragraph (9), (10), (11) or (12) (as the case may be) plus a period fixed by the Director, being not more than 85 days and corresponding to the actual interval between the third and fourth doses. |
|
6. | Sinovac‑Coronavac COVID‑19 vaccine |
|
| (1) | One dose of the approved vaccine opposite, administered to a Type T recovered individual at least 28 days after the recovered individual first tested positive for SARS‑CoV‑2. |
|
| 14th day after the dose is administered in accordance with the second column. |
| 120th day (including that day) after the day the dose is administered. |
|
| (2) | One dose of the approved vaccine opposite, administered to a Type S recovered individual after his or her recovery from the COVID‑19 infection. |
|
| 14th day after the dose is administered in accordance with the second column. |
| 120th day (including that day) after the day the dose is administered. |
|
| (3) | Two doses of the approved vaccine opposite, administered to a Type T recovered individual, the first dose of which is administered at least 28 days after the recovered individual first tested positive for SARS‑CoV‑2 and the second dose at least 13 days after the firstmentioned dose was administered. |
|
| 14th day after the second dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (4) | One dose of the approved vaccine opposite and a dose of another defined approved vaccine, administered to a Type T recovered individual, the first dose of which is administered at least 28 days after the recovered individual first tested positive for SARS‑CoV‑2 and the second dose at least 17 days after the firstmentioned dose was administered. |
|
| 14th day after the second dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (5) | Two doses of the approved vaccine opposite, administered to a Type S recovered individual after his or her recovery from the COVID‑19 infection, where the respective doses are each administered at least 13 days apart. |
|
| 14th day after the second dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (6) | One dose of the approved vaccine opposite and one dose of another defined approved vaccine, administered to a Type S recovered individual after his or her recovery from the COVID‑19 infection, where the respective doses are each administered at least 17 days apart. |
|
| 14th day after the second dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (7) | One dose of the approved vaccine opposite and a second dose of another approved vaccine that is not a defined approved vaccine, administered to a Type T recovered individual, the first dose of which is administered at least 28 days after the recovered individual first tested positive for SARS‑CoV‑2 and the second dose at least 17 days after the firstmentioned dose was administered. |
|
| 14th day after the second dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (8) | One dose of the approved vaccine opposite and a second dose of another approved vaccine that is not a defined approved vaccine, administered to a Type S recovered individual after his or her recovery from the COVID‑19 infection, where the respective doses are each administered at least 17 days apart. |
|
| 14th day after the second dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (9) | Two doses of the approved vaccine opposite, administered at least 13 days apart. |
|
| 14th day after the second dose is administered in accordance with the second column. |
| 120th day (including that day) after the day the second dose is administered. |
|
| (10) | One dose of the approved vaccine opposite, followed by a dose of another approved vaccine, administered at least 17 days after the firstmentioned dose is administered. |
|
| 14th day after the second dose is administered in accordance with the second column. |
| 120th day (including that day) after the day the second dose is administered. |
|
| (11) | Three doses of the defined approved vaccine opposite, where the first 2 doses are administered at least 13 days apart, and where the second and third doses are administered at least 17 days apart. |
|
| The day the third dose is administered in accordance with the second column. |
| 270th day (including that day) after the day the third dose is administered. |
|
| (12) | Two doses of the defined approved vaccine opposite administered at least 13 days apart, followed by a third dose either of Sinopharm COVID‑19 vaccine or another approved vaccine that is not a defined approved vaccine, where the second and third doses are administered at least 17 days apart. |
|
| The day the third dose is administered in accordance with the second column. |
| 270th day (including that day) after the day the third dose is administered. |
|
| (13) | One dose of the defined approved vaccine opposite, followed by a dose of another approved vaccine that is not a defined approved vaccine, followed by a third dose of a defined approved vaccine, where each dose is administered at least 17 days apart. |
|
| The day the third dose is administered in accordance with the second column. |
| 270th day (including that day) after the day the third dose is administered. |
|
| (14) | One dose of the defined approved vaccine opposite, followed by a dose of Sinopharm COVID‑19 vaccine, followed by a third dose of any approved vaccine, where each dose is administered at least 17 days apart. |
|
| The day the third dose is administered in accordance with the second column. |
| 270th day (including that day) after the day the third dose is administered. |
|
| (15) | Vaccination as described in paragraph (11) followed by a fourth dose of any approved vaccine administered at least 86 days after the third dose is administered. |
|
| The day the fourth dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (16) | Vaccination as described in paragraph (12), (13) or (14) followed by a fourth dose of any approved vaccine administered at least 86 days after the third dose is administered. |
|
| The day the fourth dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (17) | At least 4 doses of approved vaccines, one of which is the approved vaccine opposite, and where the third and fourth doses are administered at a shorter interval than as specified in paragraph (15) or (16) and allowed by the Director. |
|
| The day the fourth dose is administered in accordance with the second column. |
| 270th day (including that day) after the start of the period in paragraph (11), (12), (13) or (14) (as the case may be) plus a period fixed by the Director, being not more than 85 days and corresponding to the actual interval between the third and fourth doses. |
|
7. | Covaxin COVID‑19 vaccine |
|
| (1) | One dose of the approved vaccine opposite, administered to a Type T recovered individual at least 28 days after the recovered individual first tested positive for SARS‑CoV‑2. |
|
| 14th day after the dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (2) | One dose of the approved vaccine opposite, administered to a Type S recovered individual after his or her recovery from the COVID‑19 infection. |
|
| 14th day after the dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (3) | Two doses of the approved vaccine opposite, administered at least 24 days apart. |
|
| 14th day after the second dose is administered in accordance with the second column. |
| 270th day (including that day) after the day the second dose is administered. |
|
| (4) | One dose of the approved vaccine opposite, followed by a dose of another approved vaccine that is not a defined approved vaccine, administered at least 24 days after the firstmentioned dose is administered. |
|
| 14th day after the second dose is administered in accordance with the second column. |
| 270th day (including that day) after the day the second dose is administered. |
|
| (5) | One dose of the approved vaccine opposite, followed by a dose of a defined approved vaccine, administered at least 17 days after the firstmentioned dose is administered. |
|
| 14th day after the second dose is administered in accordance with the second column. |
| 120th day (including that day) after the day the second dose is administered. |
|
| (6) | Two doses of the approved vaccine opposite or one dose thereof in combination with a dose of another approved vaccine, where the doses are administered at such other intervals as may be allowed by the Director. |
|
| 14th day after the second dose is administered in accordance with the second column. |
| The following day (including that day) after the day the second dose is administered: |
(a) | 120th day where the second dose is a defined approved vaccine; |
|
(b) | 270th day for any other approved vaccine. |
|
|
| (7) | Three doses of the approved vaccine opposite, where the first 2 doses are administered at least 24 days apart, and where the second and third doses are administered at least 86 days apart. |
|
| The day the third dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (8) | Two doses of the approved vaccine opposite administered at least 24 days apart, followed by one dose of another approved vaccine administered at least 86 days after the second dose is administered. |
|
| The day the third dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (9) | One dose of the approved vaccine opposite, followed by 2 doses of another approved vaccine that is not a defined approved vaccine or a combination of approved vaccines none of which is a defined approved vaccine, where the first 2 doses are administered at least 17 days apart, and where the second and third doses are administered at least 86 days apart. |
|
| The day the third dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (10) | One dose of the approved vaccine opposite, followed by 2 doses of any defined approved vaccine or combination of defined approved vaccines, where the respective doses are each administered at least 17 days apart. |
|
| The day the third dose is administered in accordance with the second column. |
| 270th day (including that day) after the day the third dose is administered. |
|
| (11) | Vaccination in accordance with paragraph (6) where the second dose is a defined approved vaccine, followed by another dose of any defined approved vaccine, where the second and third doses are administered at least 17 days apart. |
|
| The day the third dose is administered in accordance with the second column. |
| 270th day (including that day) after the day the third dose is administered. |
|
| (12) | Vaccination in accordance with paragraph (6) where the second dose is an approved vaccine that is not a defined approved vaccine, followed by a third dose of any approved vaccine that is not a defined approved vaccine, where the second and third doses are administered at least 86 days apart. |
|
| The day the third dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (13) | At least 3 doses of approved vaccines, one of which is the approved vaccine opposite, and where the second and third doses are administered at a shorter interval than as specified in paragraph (7), (8), (9) or (12) and allowed by the Director. |
|
| The day the third dose is administered in accordance with the second column. |
| 270th day (including that day) after the day the second dose is administered plus a period fixed by the Director, being not more than 85 days and corresponding to the actual interval between the second and third doses. |
|
| (14) | Vaccination in accordance with paragraph (10) followed by a fourth dose of any approved vaccine administered at least 86 days after the third dose is administered. |
|
| The day the fourth dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (15) | At least 4 doses where vaccination is in accordance with paragraph (10) for the first 3 doses and the fourth dose is any approved vaccine, and where the third and fourth doses are administered at a shorter interval than as specified in paragraph (14) and allowed by the Director. |
|
| The day the fourth dose is administered in accordance with the second column. |
| 270th day (including that day) after the day the third dose is administered plus a period fixed by the Director, being not more than 85 days and corresponding to the actual interval between the third and fourth doses. |
|
8. | COVOVAX COVID‑19 vaccine or Nuvaxovid (Novavax COVID‑19 vaccine) |
|
| (1) | One dose of the approved vaccine opposite, administered to a Type T recovered individual at least 28 days after the recovered individual first tested positive for SARS‑CoV‑2. |
|
| 14th day after the dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (2) | One dose of the approved vaccine opposite, administered to a Type S recovered individual after his or her recovery from the COVID‑19 infection. |
|
| 14th day after the dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (3) | Two doses of the approved vaccine opposite, administered at least 17 days apart. |
|
| 14th day after the second dose is administered in accordance with the second column. |
| 270th day (including that day) after the day the second dose is administered. |
|
| (4) | One dose of the approved vaccine opposite, followed by a dose of another approved vaccine that is not a defined approved vaccine, administered at least 17 days after the firstmentioned dose is administered. |
|
| 14th day after the second dose is administered in accordance with the second column. |
| 270th day (including that day) after the day the second dose is administered. |
|
| (5) | One dose of the approved vaccine opposite, followed by a dose of a defined approved vaccine, administered at least 17 days after the firstmentioned dose is administered. |
|
| 14th day after the second dose is administered in accordance with the second column. |
| 120th day (including that day) after the day the second dose is administered. |
|
| (6) | Two doses of the approved vaccine opposite or one dose thereof in combination with a dose of another approved vaccine, where the doses are administered at such other intervals as may be allowed by the Director. |
|
| 14th day after the second dose is administered in accordance with the second column. |
| The following day (including that day) after the day the second dose is administered: |
(a) | 120th day where the second dose is a defined approved vaccine; |
|
(b) | 270th day for any other approved vaccine. |
|
|
| (7) | Three doses of the approved vaccine opposite, where the first 2 doses are administered at least 17 days apart, and where the second and third doses are administered at least 86 days apart. |
|
| The day the third dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (8) | Two doses of the approved vaccine opposite administered at least 17 days apart, followed by one dose of another approved vaccine administered at least 86 days after the second dose is administered. |
|
| The day the third dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (9) | One dose of the approved vaccine opposite, followed by 2 doses of another approved vaccine that is not a defined approved vaccine or a combination of approved vaccines none of which is a defined approved vaccine, where the first 2 doses are administered at least 17 days apart, and where the second and third doses are administered at least 86 days apart. |
|
| The day the third dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (10) | One dose of the approved vaccine opposite, followed by 2 doses of any defined approved vaccine or combination of defined approved vaccines, where the respective doses are each administered at least 17 days apart. |
|
| The day the third dose is administered in accordance with the second column. |
| 270th day (including that day) after the day the third dose is administered. |
|
| (11) | Vaccination in accordance with paragraph (6) where the second dose is a defined approved vaccine, followed by another dose of any defined approved vaccine, where the second and third doses are administered at least 17 days apart. |
|
| The day the third dose is administered in accordance with the second column. |
| 270th day (including that day) after the day the third dose is administered. |
|
| (12) | Vaccination in accordance with paragraph (6) where the second dose is an approved vaccine that is not a defined approved vaccine, followed by a third dose of any approved vaccine that is not a defined approved vaccine, where the second and third doses are administered at least 86 days apart. |
|
| The day the third dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (13) | At least 3 doses of approved vaccines, one of which is the approved vaccine opposite, and where the second and third doses are administered at a shorter interval than as specified in paragraph (7), (8), (9) or (12) and allowed by the Director. |
|
| The day the third dose is administered in accordance with the second column. |
| 270th day (including that day) after the day the second dose is administered plus a period fixed by the Director, being not more than 85 days and corresponding to the actual interval between the second and third doses. |
|
| (14) | Vaccination in accordance with paragraph (10) followed by a fourth dose of any approved vaccine administered at least 86 days after the third dose is administered. |
|
| The day the fourth dose is administered in accordance with the second column. |
| Indefinite after the start of the period. |
|
| (15) | At least 4 doses where vaccination is in accordance with paragraph (10) for the first 3 doses and the fourth dose is any approved vaccine, and where the third and fourth doses are administered at a shorter interval than as specified in paragraph (14) and allowed by the Director. |
|
| The day the fourth dose is administered in accordance with the second column. |
| 270th day (including that day) after the day the third dose is administered plus a period fixed by the Director, being not more than 85 days and corresponding to the actual interval between the third and fourth doses. |
|